Recent advances in clinical research of humanized monoclonal antibodies against respiratory syncytial virus infection in infants / 中华实用儿科临床杂志
Chinese Journal of Applied Clinical Pediatrics
; (24): 481-485, 2022.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-930463
Responsible library:
WPRO
ABSTRACT
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) and hospitalizations in infants under 1 year of age, seriously jeopardizing infants′ health.Most hospitalizations (up to 80%) due to RSV-LRTI occur in otherwise healthy infants born at term.At present, no effective treatment and preventative measure against RSV is available domestically.Passive immunization with fully human long-acting monoclonal antibody Nirsevimab offers immediate protection for all infants experiencing their first RSV season with one shot, thus ushering in a new era of prevention of RSV infection among infants.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Applied Clinical Pediatrics
Year:
2022
Document type:
Article